ETI 201
Alternative Names: ETI 104Latest Information Update: 22 Apr 2022
At a glance
- Originator Elusys Therapeutics
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 20 Apr 2022 EluSys Therapeutics has been acquired by Heat Biologics
- 23 Mar 2004 ETI 201 is available for licensing (http://www.elusys.com/)
- 09 Jul 2003 Data presented at the Annual European Congress of Rheumatology (EULAR-2003) have been added to the adverse events and Immunological Disorders pharmacodynamics section